ALCLs, independent of their ALK status, express near homogeneous CD30 positivity which renders this subtype of PTCL amenable to therapy with the CD30-targeting antibody drug conjugate brentuximab vedotin (169). Here, TNFRSF8 is linked to mature T-cell and NK-cell non-Hodgkin lymphoma.